CAI Overview

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is36.17 USD with a low forecast of 30.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Caris Life Sciences Inc revenue for the last quarter amounts to 292.89M USD, increased 125.44

Caris Life Sciences Inc. EPS for the last quarter amounts to 0.29 USD, decreased -231.82

Caris Life Sciences Inc (CAI) has 1846 emplpoyees as of April 16 2026.

Today CAI has the market capitalization of 5.92B USD.